EUVIMEDEUVIMED entdecken
Crossref

Risk Factors for the Development of Dexmedetomidine-Related Fevers in Critically-Ill Patients

Hyun A Jae iD, Karina Muzykovsky, Jose Orsini

Journal of Pharmacy Practice · 2025

DOI: 10.1177/08971900251408935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Hyun A Jae und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, The Brooklyn Hospital Center, Brooklyn, NY, USA. Hauptthemen laut MEDLINE: Dexmedetomidine, Critical Illness, Hypnotics and Sedatives, Drug Fever. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Society of Critical Care Medicine’s 2025 update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption suggest the use of dexmedetomidine over propofol for sedation in critically-ill, mechanically ventilated patients. With widespread use of dexmedetomidine, reports have been published describing development of fever with its use. Drug-induced fevers are usually a diagnosis of exclusion, making them hard to recognize, and misdiagnosis can lead to utilization of additional medications and resources. The objective of this study was to identify risk factors associated with dexmedetomidine-related fever in critically-ill patients.

Methods

This was a single-center retrospective study conducted at The Brooklyn Hospital Center, a 464-bed community teaching hospital. Adult patients, admitted to the intensive care unit, who received at least 12 hours of continuous dexmedetomidine infusion were included. Univariate and multivariate logistic regression analyses were conducted to identify the risk factors for dexmedetomidine-related fever.

Results

Eighty one patients were included, of whom 31 (38.3%) were febrile and 50 (61.7%) were afebrile while receiving dexmedetomidine infusion. Multivariate analysis showed higher likelihood of developing fever if patients received dexmedetomidine continuously for ≥72 hours (OR 5.97, 95% CI 1.90-18.75) and if dexmedetomidine rate was ≥1 mcg/kg/hr at Tmax (OR 6.16, 95% CI 1.80-21.09).

Conclusion

Dexmedetomidine infusion for 72 hours or longer and dexmedetomidine infusion rate at 1 mcg/kg/hr or greater were risk factors for developing a fever in critically ill patients in a community teaching hospital.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineCritical IllnessHypnotics and SedativesDrug FeverFeverHumansRisk FactorsRetrospective StudiesFemaleMaleMiddle AgedAgedIntensive Care UnitsAdult

Stichwörter der Autor:innen

critically illdexmedetomidinefeverrisk factors

Substanzen

DexmedetomidineHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Pharmacotherapy, The Brooklyn Hospital Center, Brooklyn, NY, USA.
  • Department of Medicine, The Brooklyn Hospital Center, Brooklyn, NY, USA.

ORCID-Profile: Hyun A Jae

Zitieren

APA

Jae, H. A., Muzykovsky, K., & Orsini, J. (2025). Risk Factors for the Development of Dexmedetomidine-Related Fevers in Critically-Ill Patients. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900251408935

Vancouver

Jae HA, Muzykovsky K, Orsini J. Risk Factors for the Development of Dexmedetomidine-Related Fevers in Critically-Ill Patients. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900251408935

BibTeX
@article{Jae2025,
  author = {Jae, Hyun A and Muzykovsky, Karina and Orsini, Jose},
  title = {Risk Factors for the Development of Dexmedetomidine-Related Fevers in Critically-Ill Patients},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  doi = {10.1177/08971900251408935}
}
Kostenlos starten →